FibroBiologics Announces Complete Payoff of Outstanding Debt
FibroBiologics has repaid all amounts outstanding under its Yorkville-issued convertible promissory notes, removing the prospect of further conversions into...
Tangram Announces New Phase 1/2 Trial for MASH Candidate
Tangram Therapeutics has submitted a Clinical Trial Application to the UK MHRA to begin a Phase 1/2 study of...
Hope for ALS: Tiziana’s Nasal Trial Enters Healey Program
Tiziana Life SciencesLife Sciences’ intranasal anti-CD3 antibody, foralumab, has been accepted into the ALS MyMatch Program at the Healey...
BriaCell Unveils Promising Phase 2/3 Data at SABCS 2025
BriaCell will present survival readouts from its Phase 2 study of the allogeneic whole cell vaccine Bria-IMT and new...
Kymera Launches Phase 2b Trial for New Atopic Dermatitis Drug
Kymera has begun dosing in BROADEN2, a 16-week, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in moderate to...
New ENIGMAC Data Reveals Macrophage Role in Fibrotic Disease
Macomics has validated its ENIGMAC macrophage discovery platform in antifibrotic biology, completing pooled and arrayed CRISPR-based gene modulation screens...
Junshi Announces Successful Phase 3 NSCLC Study Results
Junshi Biosciences reported that its Phase 3 JS001sc-002-III-NSCLC study met primary endpoints, showing non-inferior drug exposure for subcutaneous toripalimab...
Gelteq’s Promising Gel Tech: A Bioavailability Victory
Gelteq reported a 38–45% increase in AUC and a markedly higher Cmax versus a marketed reference antihistamine in a...
Important New Elzonris Data Presented at Hematology Meeting
Menarini and Stemline will bring five ELZONRIS (tagraxofusp) data sets to ASH 2025, headlined by an oral Phase 2...
Cidara’s Phase 3 Flu Prevention Trial Hits Target Enrollment
Cidara completed enrollment of 6,000 participants in its Phase 3 ANCHOR trial of CD388, a single 450 mg subcutaneous...